Frontier IP Group plc Exscientia Wins Emerging Biotech Company Award
October 09 2017 - 1:00AM
RNS Non-Regulatory
TIDMFIPP
Frontier IP Group plc
09 October 2017
RNS REACH
AIM: FIPP
9(th) October 2017
Frontier IP Group Plc
("Frontier IP" or the "Group")
Portfolio News
Exscientia Wins Best Emerging Biotech Company Award
Frontier IP, which specialises in the commercialisation of
intellectual property, is pleased to announce that its portfolio
company Exscientia Limited ("Exscientia") was the winner of the
Best Emerging Biotech Company Award at the OBN Annual Awards
ceremony, celebrating outstanding achievement in the UK life
sciences sector, held 5th October in Oxford, UK. The full text of
this announcement is set out below.
Exscientia Wins Best Emerging Biotech Company Award at OBN
Annual Awards 2017
Exscientia, the leading Artificial Intelligence (AI)-driven drug
discovery company, is pleased to announce that it was the winner of
the Best Emerging Biotech Company Award at the OBN Annual Awards
ceremony, celebrating outstanding achievement in the UK life
sciences sector, held 5th October in Oxford, UK.
The award was presented to Andrew Hopkins, CEO of Exscientia, in
recognition of the company's outstanding success in applying AI and
big data processing to accelerate drug discovery and development.
This success is highlighted by the company's collaborations with
GSK, Sanofi and Evotec, representing a strong endorsement of
Exscientia and validation of its approach. Through these
collaborations, the company is developing single-target small
molecules as well as compounds with more challenging target product
profiles, through a novel bispecific small molecule strategy
(compounds with dual pharmacology in an integrated pharmacophore)
and phenotypic-driven drug design.
This award was judged by a panel of leading figures from the UK
life sciences industry.
OBN is the membership organisation supporting and bringing
together the UK's emerging life sciences companies, corporate
partners and investors. www.obn.org.uk
About the OBN Annual Awards - www.obn-awards.com
The OBN Awards 2017, now in their 9th year, celebrate innovation
and outstanding achievement across the UK Life Sciences industry.
Categories are broad ranging and include Biotech, Medtech,
Synthetic Biology, Digital Healthcare and Investment. This year
they also launched a new category, Best CRO which looks to
recognise the critical support services provided by Contract
Research Organisations across the pharmaceutical, biotech and
medtech industries.
NOTES FOR EDITORS
About Exscientia and AI-Driven Drug Discovery
Exscientia is at the forefront of Artificial Intelligence
(AI)-driven drug discovery and design. By fusing the power of AI
with the discovery experience of seasoned drug hunters, Exscientia
is the first company to automate drug design, surpassing
conventional approaches.
Exscientia's innovative platform enables breakthrough
productivity gains as well as new approaches to improve drug
efficacy. Novel compounds prioritised for synthesis by its AI
systems simultaneously balance potency, selectivity and
pharmacokinetic criteria in order to deliver successful
experimental outcomes.
By applying a rapid design-make-test cycle, the Exscientia AI
platform actively learns from the preceding experimental results
and rapidly evolves compounds towards the desired candidate
criteria.
Exscientia systems learn from both existing data resources and
experimental data from each design cycle. The principle is similar
to how a human would learn, but the AI process is far more
effective at identifying and assimilating multiple subtle and
complex trends to balance potency, selectivity and pharmacokinetic
criteria.
As a result, the AI-driven process is more likely to achieve the
end goal and to do this more rapidly and efficiently than
traditional human endeavour.
Exscientia is collaborating with several leading pharmaceutical
companies. In addition to Evotec, partners include Sanofi
(metabolic disease), Sumitomo Dainippon Pharma and Sunovion
Pharmaceuticals (CNS) and GSK.
Exscientia was established as a spinout company from Prof.
Andrew Hopkins' laboratory at the University of Dundee.
For more information visit www.exscientia.co.uk
Follow on Twitter www.twitter.com/exscientialtd
ENDS
For further information:
Frontier IP Group Plc T: 0131 240 1251
Neil Crabb, Chief Executive
Company website: www.frontierip.co.uk
Cenkos Securities plc (Nominated T: 0131 220 6939
Adviser and Joint Broker)
Neil McDonald / Beth McKiernan
Peterhouse Corporate Finance T: 020 7469 0935
Limited (Joint Broker)
Lucy Williams
Kreab (Financial PR) T: 020 7074 1800
Robert Speed / Matthew Jervois
Notes to Editor:
About Frontier IP Group plc
www.frontierip.co.uk.
Frontier IP specialises in assisting institutions and companies
in the commercialisation and exploitation of their intellectual
property. It establishes formal and informal relationships with
sources of exploitable IP, principally universities. Its core
business is building and growing a portfolio of equity stakes in
spin-out companies by taking an active involvement in the
commercialisation and funding of these businesses.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFSWFMMFWSEFS
(END) Dow Jones Newswires
October 09, 2017 02:00 ET (06:00 GMT)
Frontier Ip (LSE:FIPP)
Historical Stock Chart
From Apr 2024 to May 2024
Frontier Ip (LSE:FIPP)
Historical Stock Chart
From May 2023 to May 2024